Start Printed Page 664
Drug Enforcement Administration (DEA), Department of Justice.
On July 9, 2012, the President signed into law the Synthetic Drug Abuse Prevention Act of 2012 (SDAPA). SDAPA amends the Controlled Substances Act by placing 26 substances in Schedule I. DEA is publishing this rule to establish drug codes for these 26 substances, and to make technical and conforming amendments in accordance with SDAPA.
Effective Date: January 4, 2013.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
John W. Partridge, Executive Assistant, Office of Diversion Control, Drug Enforcement Administration, Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone (202) 307-7165.
End Further Info
Start Supplemental Information
DEA administers, implements, and enforces Titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, often referred to as the Controlled Substances Act and the Controlled Substances Import and Export Act (21 U.S.C. 801-971), as amended (hereinafter, “CSA”). The implementing regulations for these statutes are found in Title 21 of the Code of Federal Regulations (CFR), parts 1300 to 1321. Under the CSA, controlled substances are classified in one of five schedules based upon their potential for abuse, their currently accepted medical use, the lack of accepted safety for use under medical supervision, and the degree of dependence the substance may cause. 21 U.S.C. 812. The list of legislatively scheduled controlled substances is found at 21 U.S.C. 812(c) and the current list of scheduled substances is published at 21 CFR part 1308. These initial schedules may be modified either by legislation or by rulemaking.
Purpose of This Rulemaking
On July 9, 2012, the SDAPA of 2012, Public Law 112-144, Title XI, Subtitle D, became effective. SDAPA amended the CSA by legislatively placing “cannabimimetic agents” 
and 26 substances in Schedule I. Public Law 112-144, Title XI, Subtitle D, Section 1152. DEA is publishing this rule to establish drug codes for these 26 substances. These 26 substances include 15 cannabimimetic agents, 9 phenethylamines, and 2 cathinones and are listed in the regulatory text section, below.
Related Procedural Matters
At the time SDAPA became effective on July 9, 2012, a total of 8 substances were covered by temporary scheduling final orders: 5 synthetic cannabinoids (JWH-018, JWH-073, JWH-200, CP-47,497, and CP-47,497 C8 homologue) 
and 3 synthetic cathinones (mephedrone, MDPV, and methylone).
DEA also issued a Notice of Proposed Rulemaking (NPRM) in March 2012, to place the 5 synthetic cannabinoids (JWH-018, JWH-073, JWH-200, CP-47,497, and CP-47,497 C8 homologue) permanently in Schedule I.
With the sole exception of methylone,
these substances were specifically placed in Schedule I by SDAPA. Therefore, it is no longer necessary to finalize the NPRM regarding the 5 synthetic cannabinoids (JWH-018, JWH-073, JWH-200, CP-47,497, and CP-47,497 C8 homologue), or to take further action with respect to 2 of the 3 synthetic cathinones (mephedrone and MDPV). However, DEA has posted a copy of the Secretary of Health and Human Services (HHS) Scientific and Medical Evaluation and Scheduling Recommendations regarding the 5 synthetic cannabinoids on www.regulations.gov so that the public can benefit from the scientific review that was undertaken with respect to these substances.
These HHS documents can be found on www.regulations.gov under Docket ID “DEA-2012-0001.”
In addition to establishing drug codes for these 26 substances,
this rulemaking makes several technical and conforming amendments to 21 CFR 1308.11 in accordance with SDAPA. This rulemaking adds a new subsection (g) to 21 CFR 1308.11 and gives it the title “cannabimimetic agents,” redesignates the old subsection (g) as (h) and retains its title as “[t]emporary listing of substances subject to emergency scheduling,” and transfers 7 of the 8 substances currently listed in 21 CFR 1308.11(g) under the title of “[t]emporary listing of substances subject to emergency scheduling,” to either the new subsection (g) entitled “cannabimimetic agents” or to the previously existing subsection (d) entitled “[h]allucinogenic substances.” In summary, as a result of SDAPA, a new subsection entitled “cannabimimetic agents” will be created and will initially contain 15 substances, the existing subsection entitled “[h]allucinogenic substances” will increase by 11 substances, and the existing subsection entitled “temporary listing of substances subject to emergency scheduling” will be redesignated from (g) to (h) and will decrease from 8 substances to 1 substance (methylone).
Start Printed Page 665
Administrative Procedure Act
An agency may find good cause to exempt a rule from certain provisions of the Administrative Procedure Act (APA) (5 U.S.C. 553), including notice of proposed rulemaking and the opportunity for public comment, if it is determined to be unnecessary, impracticable, or contrary to the public interest. This rule merely establishes drug codes for the 26 substances placed in Schedule I by SDAPA, and makes several technical and conforming amendments in accordance with SDAPA. Because DEA has no discretion with respect to these changes, publishing a notice of proposed rulemaking and soliciting public comment are unnecessary. In addition, because the placement of these 26 substances in Schedule I has already been in effect since July 9, 2012, DEA finds good cause exists to make this rule effective immediately upon publication.
Executive Orders 12866 and 13563
This rule, establishing drug codes for the 26 substances placed in Schedule I by SDAPA, and making technical and conforming amendments in accordance with SDAPA has been developed in accordance with the principles of Executive Orders 12866 and 13563.
This regulation meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform to eliminate ambiguity, minimize litigation, establish clear legal standards, and reduce burden.
This rulemaking does not preempt or modify any provision of State law, impose enforcement responsibilities on any State, or diminish the power of any State to enforce its own laws. Accordingly, this rulemaking does not have federalism implications warranting the application of Executive Order 13132.
This rule is required by statute, will not have tribal implications, and will not impose substantial direct compliance costs on Indian tribal governments.
Regulatory Flexibility Act
The Deputy Administrator hereby certifies that this rulemaking has been drafted in accordance with the Regulatory Flexibility Act (5 U.S.C. 601-612), has reviewed this regulation, and by approving it certifies that this regulation will not have a significant economic impact on a substantial number of small entities.
Paperwork Reduction Act of 1995
This rule does not involve a collection of information within the meaning of the Paperwork Reduction Act of 1995, 44 U.S.C. 3501-3521.
Unfunded Mandates Reform Act of 1995
This rule will not result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $136,000,000 or more (adjusted for inflation) in any one year, and will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995. 2 U.S.C. 1532.
Congressional Review Act
This rule is not a major rule as defined by the Congressional Review Act (5 U.S.C. 804). This rule will not result in an annual effect on the economy of $100,000,000 or more, a major increase in cost or prices, or have significant adverse effects on competition, employment, investment, productivity, innovation, or the ability of United States-based companies to compete with foreign based companies in domestic and export markets. However, DEA has submitted a copy of this rule to both Houses of Congress and to the Comptroller General.
Start List of Subjects
End List of Subjects
- Administrative practice and procedure
- Drug traffic control
- Reporting and recordkeeping requirements
For the reasons set out above, 21 CFR part 1308 is amended as follows:
PART 1308—SCHEDULES OF CONTROLLED SUBSTANCES
Start Amendment Part
1. The authority citation for part 1308 continues to read as follows: End Amendment Part
Start Amendment Part
2. Amend § 1308.11 by: End Amendment Part
Start Amendment Part
a. Adding new paragraphs (d)(36) through (d)(46); End Amendment Part
Start Amendment Part
b. Redesignating paragraph (g) as paragraph (h) and revising newly redesignated paragraph (h)(1); and End Amendment Part
Start Amendment Part
c. Adding a new paragraph (g). End Amendment Part
The additions and revisions read as follows:
* * * * *
(d) * * *
|(36) 4-methylmethcathinone (Mephedrone)||1248|
|(37) 3,4-methylenedioxypyrovalerone (MDPV)||7535|
|(38) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)||7509|
|(39) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)||7508|
|(40) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)||7519|
|(41) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)||7518|
|(42) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)||7385|
|(43) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)||7532|
|(44) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)||7517|
|(45) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)||7521|
|(46) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)||7524|
* * * * *
(g) Cannabimimetic agents. Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
|(1) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497)||7297|
|(2) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog)||7298|
|(3) 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)||7118|
|(4) 1-butyl-3-(1-naphthoyl)indole (JWH-073)||7173|
|(5) 1-hexyl-3-(1-naphthoyl)indole (JWH-019)||7019|
|(6) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)||7200|
|(7) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)||6250|
|(8) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)||7081|
|(9) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)||7122|
|(10) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)||7398|
|(11) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201)||7201|
|(12) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)||7694|
|Start Printed Page 666|
|(13) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4)||7104|
|(14) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole 7008 (SR-18 and RCS-8)||7008|
|(15) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)||7203|
(h) * * *
|(1) 3,4-methylenedioxy-N-methylcathinone (Other names: methylone)||7540|
* * * * *
End Supplemental Information
Dated: December 21, 2012.
Michele M. Leonhart,
[FR Doc. 2012-31698 Filed 1-3-13; 8:45 am]
BILLING CODE 4410-09-P